| dc.contributor |
Universitat de Vic. Càtedra de la Sida i Malalties Relacionades |
| dc.contributor.author |
Santos, José R. |
| dc.contributor.author |
Saumoy, M. |
| dc.contributor.author |
Curran, Adrian |
| dc.contributor.author |
Bravo, Isabel |
| dc.contributor.author |
Navarro, Jordi |
| dc.contributor.author |
Estany, Carla |
| dc.contributor.author |
Podzamczer Palter, Daniel |
| dc.contributor.author |
Ribera, Esteban |
| dc.contributor.author |
Negredo, Eugenia |
| dc.contributor.author |
Clotet, Bonaventura |
| dc.contributor.author |
Paredes, Roger |
| dc.date |
2014 |
| dc.identifier |
Ramon Santos, J., Saumoy, M., Curran, A., Bravo, I., Navarro, J., Estany, C., et al. (2014). Randomized, crossover, double-blind, placebo-controlled trial to assess the lipid lowering effect of co-formulated TDF/FTC. Journal of the International Aids Society, 17, 42-42. |
| dc.identifier |
1758-2652 |
| dc.identifier |
http://hdl.handle.net/10854/3793 |
| dc.identifier |
https://doi.org/10.7448/IAS.17.4.19550 |
| dc.identifier.uri |
http://hdl.handle.net/10854/3793 |
| dc.description |
Abstract
INTRODUCTION:
Previous studies have described improvements on lipid parameters when switching from other antiretroviral drugs to tenofovir (TDF) and impairments in lipid profile when discontinuing TDF. [1-3] It is unknown, however, if TDF has an intrinsic lipid-lowering effect or such findings are due to the addition or removal of other offending agents or other reasons.
MATERIALS AND METHODS:
RESULTS:
46 subjects with a median age of 43 (40-48) years were enrolled in the study: 70% were male, 56% received DRV/r and 44% LPV/r. One subject withdrew the study voluntarily at week 4 and another one interrupted due to diarrhoea at week 24. Treatment with TDF/FTC decreased total, LDL and HDL-cholesterol from 235.9 to 204.9 (p<0.001), 154.7 to 127.6 (p<0.001) and 50.3 to 44.5 mg/dL (p<0.001), respectively. In comparison, total, LDL and HDL-cholesterol levels remained stable during placebo exposure. Week 12 total cholesterol (p<0.001), LDL-cholesterol (p<0.001) and HDL-cholesterol (p=0.011) levels were significantly lower in TDF/FTC versus placebo. Treatment with TDF/FTC reduced the fraction of subjects with abnormal fasting total-cholesterol (≥200 mg/dL) from 86.7% to 56.8% (p=0.001) and LDL-cholesterol (≥130 mg/dL) from 87.8% to 43.9% (p<0.001), which was not observed with placebo. There were no virological failures, and CD4 and triglyceride levels remained stable regardless of exposure.
CONCLUSION:
Coformulated TDF/FTC has an intrinsic lipid-lowering effect, likely attributable to TDF. |
| dc.format |
application/pdf |
| dc.language |
eng |
| dc.publisher |
International AIDS Society |
| dc.rights |
Aquest document està subjecte a aquesta llicència Creative Commons |
| dc.rights |
http://creativecommons.org/licenses/by/3.0/es/ |
| dc.rights |
info:eu-repo/semantics/openAccess |
| dc.subject |
Sida -- Tractament |
| dc.title |
Randomized, crossover, double-blind, placebo-controlled trial to assess the lipid lowering effect of co-formulated TDF/FTC |
| dc.type |
info:eu-repo/semantics/article |
| dc.type |
info:eu-repo/publishedVersion |
